Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00211523
Status:
COMPLETED
Last Update Posted:
2005-09-21
First Post:
2005-09-13
Brief Title:
Safety and Efficacy of MBI 226 25 and 50 Topical Acne Solutions in the Treatment of Acne
Sponsor:
BioWest Therapeutics Inc
Organization:
BioWest Therapeutics Inc
Study Overview
Official Title:
Phase II Randomized Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of MBI 226 25 and 50 Acne Solutions Applied Topically for 6 Weeks to Subjects With Acne Vulgaris
Status:
COMPLETED
Status Verified Date:
2005-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study investigates the safety and efficacy of MBI 226 25 and 50 Acne Solutions applied topically for six weeks in the treatment of acne
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None